trending Market Intelligence /marketintelligence/en/news-insights/trending/gOXKQrv47lHw6NM43iFkvQ2 content esgSubNav
In This List

Jazz Pharmaceuticals, Codiak BioSciences partner to develop cancer drugs

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Jazz Pharmaceuticals, Codiak BioSciences partner to develop cancer drugs

Jazz Pharmaceuticals PLC said it entered a collaboration with privately held Codiak Biosciences Inc. to develop up to five classes of cancer therapies.

Cambridge, Mass.-based Codiak granted Jazz an exclusive, worldwide license to commercialize therapies directed at five targets to be developed using its exosomes-based technology.

Exosomes are structures released by the cells that are shown to carry molecular messages between tumor and immune cells and can be a key to treat cancer.

Under the deal, Dublin-based Jazz Pharmaceuticals will pay Codiak $56 million up front plus up to $200 million in milestones for each of five targets. The deal also includes additional payments of preclinical development milestones of up to $20 million along with royalties on future net sales.

Codiak, which will handle the early-stage development of the drugs, will also retain an option to co-commercialize up to two products in the U.S. and Canada.

After the completion of phase 1/2 studies by Codiak, Jazz will be responsible for developing and commercializing all the products.